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Background: Growth differentiation factor 11 (GDF11) is reported to possess anti-aging 
and rejuvenating effects, including muscle regeneration and to be highly expressed in skeletal 
muscle. Recently, we demonstrated that the levels of plasma GDF11 were decreased in COPD. 
However, the effect of decreased circulating GDF11 in the pathophysiology of COPD remains 
unknown. The aim of this study is to investigate the association between the plasma GDF11 
levels and various clinical parameters in patients with COPD.
Patients and methods: Eighteen ex-smokers as control subjects and 70 COPD patients 
participated in the current study. We measured the levels of plasma GDF11 using immuno-
blotting, lung function, physical activity using a triaxial accelerometer, quadriceps strength, 
exercise capacity, and systemic inflammatory markers. We investigated the association between 
the levels of plasma GDF11 and these clinical parameters.
Results: The levels of plasma GDF11 in the COPD patients had significant positive correlations 
with the data of lung function. Furthermore, the levels of plasma GDF11 were significantly 
correlated with the physical activity, quadriceps strength, and exercise capacity. Moreover, the 
levels of plasma GDF11 were significantly correlated with the data of inflammatory markers. 
Although various factors were related to GDF11, the multiple regression analysis showed that 
physical activity was significantly associated with the levels of plasma GDF11.
Conclusion: Physical inactivity was significantly related to the decreased GDF11 levels in 
COPD, which might be useful for understanding the pathogenesis of COPD. Clarifying the 
relationships between the physical inactivity and GDF11 may reveal a potentially attractive 
therapeutic approach in COPD via increasing the plasma levels of GDF11.
Keywords: physical activity, muscle strength, rejuvenating factor, COPD
Introduction
There is increasing evidence that senescence plays a crucial role in the pathogenesis of 
COPD.1–4 In fact, cellular senescence in various resident cells is accelerated in COPD 
lungs.5–7 Senescence of lung resident cells is reported to cause destruction of the normal 
lung architecture2,3,5 and is believed to be associated with the systemic inflammation 
observed in COPD.8–10 In this context, the acceleration of lung cellular senescence 
could be involved in the development and progress of the disease.
Growth differentiation factor 11 (GDF11) is a member of the transforming growth 
factor beta superfamily.11 GDF11 has been focused on as an anti-aging and rejuvenating 
factor.12–14 In particular, Sinha et al showed that treatment with GDF11 regenerated 
the injured muscle and restored satellite cell function, resulting in increased muscle 
strength and exercise endurance in aged mice.14 The expression of GDF11 was 
Correspondence: hisatoshi sugiura
Department of respiratory Medicine, 
Tohoku University graduate school of 
Medicine, 1-1 seiryo-machi, aoba-ku, 
sendai 980-8574, Japan
Tel +81 22 717 8539
Fax +81 22 717 8549
email sugiura@rm.med.tohoku.ac.jp 
Journal name: International Journal of COPD
Article Designation: Original Research
Year: 2018
Volume: 13
Running head verso: Tanaka et al
Running head recto: GDF11 and physical activity in COPD
DOI: 157035
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
6.
77
.5
6.
92
 o
n 
21
-A
pr
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1334
Tanaka et al
observed in various organs of mice and highly present in 
skeletal muscle.12
Recently, we demonstrated that the production of GDF11 
in lung fibroblasts and airway epithelial cells from patients 
with COPD was decreased compared with those from control 
subjects.15 We showed that treatment with GDF11 inhibited 
the cigarette smoke extract (CSE)-induced cellular senes-
cence and inflammation in lung resident cells.15 We also 
demonstrated that the administration of GDF11 suppressed 
the elastase-induced cellular senescence and enlargement 
of alveolar spaces in vivo,15 suggesting that GDF11 might 
be involved in the pathogenesis of COPD. Furthermore, 
we found that the amounts of plasma GDF11 in patients 
with COPD were decreased compared with those in control 
subjects.15 However, it remains unknown whether there is 
an association between the decrease in plasma GDF11 and 
various clinical data related to the pathogenesis of COPD.
In the current study, we aimed to investigate the correla-
tion between the levels of plasma GDF11 and various clinical 
parameters, including lung function, physical activity, quad-
riceps strength, exercise capacity, and systemic inflammatory 
markers in patients with COPD.
Materials and methods
study subjects
Seventy outpatients with COPD and 18 age-matched healthy 
subjects were recruited into the current study from Tohoku 
University Hospital, Tohoku Rosai Hospital, and Tohoku 
Medical and Pharmaceutical University Wakabayashi 
Hospital. The study subjects were enrolled from separate 
cohorts of a previous study.15 All patients with COPD were 
aged .40 years, had a former smoking history of .10 
pack-years, and were diagnosed according to the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) 
documents.16 Age-matched control subjects with a smoking 
history of .10 pack-years and normal lung function were 
enrolled. All patients with COPD and control subjects had 
been free of infections of the respiratory tract and exacerba-
tions due to any reasons for at least 2 months prior to the study. 
All participants had quit smoking for at least 1 year. Patients 
with COPD and control subjects with pathologic conditions, 
including cerebrovascular diseases, rheumatoid arthritis, and 
arteriosclerosis obliterans, which affected the physical activity, 
were excluded from the study. Written informed consent was 
obtained from all subjects. All experiments in the current study 
were approved by the ethics committee of Tohoku University 
Graduate School of Medicine (approval number: #2013-1-074), 
Tohoku Rosai Hospital (approval number: #15-11), 
and Tohoku Medical and Pharmaceutical University 
Wakabayashi Hospital (approval number: #2015-1-024).
study design
Lung function tests were performed using CHESTAC-8800 
(Chest Ltd., Tokyo, Japan) and whole blood was collected 
into vacutainer tubes containing an anticoagulant. The 
plasma samples were obtained by centrifugation of the 
tubes at 3,000 rpm for 10 minutes and then stored at −80°C 
until the assay. Physical activity was measured by a triaxial 
accelerometer for 2 weeks and the levels of physical activity 
were analyzed. Then, the exercise capacity was measured by 
means of 6-minute walking tests, after which the quadriceps 
strength was measured.
Measurement of plasma gDF11 levels
The levels of plasma GDF11 were assessed by immunoblotting.15 
The plasma samples were diluted with saline and the diluted 
samples were mixed with sample buffer (Bio-Rad Labora-
tories, Hercules, CA, USA). Equal amounts of protein were 
loaded and separated by electrophoresis on 10% sodium 
dodecyl sulfate polyacrylamide gels. After electrophoresis, 
the separated proteins were transferred to a polyvinylidene 
difluoride membrane (Merck Millipore Ltd., Darmstadt, 
Germany). We used a different antibody raised against GDF11 
specifically that does not recognize myostatin (1:1,000 dilu-
tion, R&D Systems Inc., Minneapolis, MN, USA).15 Bound 
antibodies were visualized using a peroxidase-conjugated 
anti-mouse goat antibody (1:2,000 dilution, Santa Cruz 
Biotechnology Inc., Dallas, TX, USA) and enhanced chemi-
luminescence (GE Healthcare Ltd., Buckinghamshire, UK) 
with a chemiluminescence imaging system (LAS-4000 
mini; Fujifilm CO., Tokyo, Japan). Ponceau S staining was 
used to evaluate the amounts of protein. The GDF11 levels 
were calculated by measuring the intensity of the bands. 
Band intensity was quantified using ImageJ 1.48v software 
(National Institutes of Health, Bethesda, MD, USA).
assessment of physical activity
Physical activity was measured by a triaxial accelerometer 
(Actimarker; Panasonic CO., Osaka, Japan), which can 
continuously monitor activity for over 1 month, as previ-
ously reported.17,18 Briefly, patients wore the accelerometer 
during the daytime for 14 consecutive days. From among the 
14 days monitoring data, except the first and last days, the 
data of 5 non-rainy weekdays were analyzed according to 
previous studies.17–19 We measured the parameters of physical 
activity as follows: number of steps, duration of activity 
at $2.0, $2.5, and $3.0 metabolic equivalents (METs).
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Measurement of quadriceps strength
Isometric quadriceps maximum voluntary contraction 
(QMVC) was assessed using an Biodex System3 Dynamometer 
(Biodex Medical Systems, Shirley, NY, USA). The subjects 
were seated and their hip and knee joints were flexed at 90 
degrees. The subjects performed isometric contraction for 3 
seconds, the maximum force was measured, and predicted 
QMVC was calculated as described in a previous report.20
Measurements of 6-minute walking 
distance (6MWD)
The 6MWD was measured according to American Thoracic 
Society guidelines.21
Measurement of plasma levels of 
interleukin-6 (Il-6), high sensitivity 
C-reactive protein (hs-CRP), fibrinogen, 
and malondialdehyde (MDa)
Plasma IL-6 and hs-CRP were measured by a commercially 
available enzyme-linked immunosorbent assay kit (R&D 
Systems Inc.), according to the manufacturer’s instructions. 
Fibrinogen was measured using an automatic blood coagula-
tion analyzer (CS-5100; Sysmex CO., Kobe, Japan). MDA, 
which is a marker of lipid peroxidation, was measured as 
thiobarbituric acid reactive substances according to the manu-
facturer’s instructions (Abcam plc., Cambridge, UK).
statistical analysis
When we designed this study, we consulted with a statistician 
in our institution and he estimated how many subjects were 
needed in this study. Based on our statistician’s opinion, we 
calculated the appropriate sample sizes using the values of 
α = 0.05, effect size = 0.3, and 1-β = 0.7. Accordingly, at least 
67 patients were needed. In the current study, we included 
70 patients in the study.
The data are expressed as mean ± SD or median (inter-
quartile range) as appropriate. Comparisons of the number 
of steps, duration of activity, and 6MWD between the groups 
were analyzed with Kruskal–Wallis test followed by Dunn’s 
test. The remaining data were statistically analyzed with one-
way analysis of variance followed by Tukey’s test. Statistical 
correlation analyses were performed using Spearman’s test. 
A linear regression analysis was performed using the method 
of least squares. Multivariable models were used to determine 
associations between GDF11 and other variables. Multiple 
regression analysis was performed using GDF11 as the depen-
dent variable. The independent variables were selected using 
a stepwise approach and included in the model (ie, number of 
steps and QMVC). Potential confounders, such as lung func-
tion, exercise capacity, and inflammatory markers were also 
included in the model if they showed statistical significance 
(p , 0.05). Among the parameters of lung function, forced 
vital capacity (FVC) % predicted, forced expiratory volume 
in 1 second (FEV
1
) % predicted, inspiratory capacity (IC), and 
diffusing capacity of the lung for carbon monoxide (D
Lco
’) % 
predicted showed statistical significance by univariate analy-
sis. To avoid multicollinearity, we selected FEV
1
 % predicted 
in this model. Smoking history (pack-years) was included 
in the model and was independent of statistical significance. 
Statistical analysis was performed using GraphPad Prism 6 
(GraphPad Software Inc., San Diego, CA, USA) and JMP 
v12 Pro (SAS Institute Inc., Cary, NC, USA). p-values ,0.05 
were considered significant.
Results
relationship between gDF11 levels and 
lung function
Eighteen control subjects and 70 patients with COPD (GOLD 
stage I/II, n=37; GOLD stage III/IV, n=33) took part in the 
current study. The characteristics of the study subjects are 
listed in Table 1. Compatible with the previous study,15 
Table 1 Characteristics of the study subjects
Control COPD
GOLD I/II GOLD III/IV
subjects, n 18 37 33
age, years 69.2±6.2 70.1±5.5 71.2±6.2
Males/females 17/1 36/1 33/0
smoking, 
pack-years
30.5±11.4 60.0±27.5* 61.3±30.5*
BMI, kg/m2 24.0±3.2 23.6±3.2 21.0±3.5*,‡
mMrC dyspnea 
score
0.1±0.2 0.9±0.8* 1.9±1.0*,‡
FVC, % predicted 108.3±12.7 99.5±16.0 73.6±19.0*,‡
FeV1, % predicted 103.0±13.1 70.8±12.2* 32.6±10.8*,‡
FeV1/FVC, % 77.5±4.4 58.1±9.0* 35.7±8.7*,‡
IC, l 2.8±0.5 2.3±0.4* 1.8±0.5*,‡
Dlco’, % predicted 112.3±27.1 70.0±25.4* 43.2±22.6*,‡
6MWD, m 510 (470–558) 450 (400–484)* 350 (208–402)*,‡
laBa, n – 23 29
laMa, n – 27 33
ICs, n – 8 11
Notes: Data are presented as mean ± sD or median (IQr). *p , 0.01 versus control, 
‡p , 0.01 versus gOlD I/II.
Abbreviations: BMI, body mass index; Dlco’, diffusing capacity of the lung for 
carbon monoxide; FeV1, forced expiratory volume in 1 second; FVC, forced vital 
capacity; gOlD, global Initiative for Chronic Obstructive lung Disease; IC, 
inspiratory capacity; ICs, inhaled corticosteroids; IQr, interquartile range; laBa, 
long-acting β2 agonist; LAMA, long-acting muscarinic antagonist; mMRC, modified 
Medical research Council; 6MWD, 6-minute walking distance.
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the levels of plasma GDF11 measured by immunoblotting 
were significantly decreased in the patients with COPD 
compared with those in the control subjects (Figure S1). 
We investigated the association between the plasma GDF11 
levels and lung function. The levels of plasma GDF11 in 
the COPD patients had significantly positive correlations 
with the values of FEV
1
 % predicted (r = 0.48, p , 0.001, 
Figure 1A), FVC % predicted (r = 0.39, p = 0.001, Figure 1B), 
IC (r = 0.41, p , 0.001, Figure 1C), and D
Lco
’ % predicted 
(r = 0.36, p = 0.003, Figure 1D).
relationship between gDF11 levels and 
physical activity
The physical activity measured by a triaxial accelerometer 
and the data of physical activity given in daily number of 
steps and intensity of physical activity (METs) are shown in 
Table 2. All data of the physical activity were significantly 
lower in the GOLD stage III/IV patients compared with 
those in the control subjects and GOLD stage I/II patients 
(Table 2). The levels of plasma GDF11 were significantly 
correlated with the number of steps (r = 0.65, p , 0.001, 
Figure 2A), duration of $2.0 METs (r = 0.57, p , 0.001, 
Figure 2B), $2.5 METs (r = 0.59, p , 0.001, Figure 2C), 
and $3.0 METs (r = 0.53, p , 0.001, Figure 2D).
relationship between gDF11 levels and 
muscle strength and exercise capacity
Because GDF11 is reported to be highly expressed in skel-
etal muscle,12 we investigated the relationship between the 
GDF11 levels and muscle strength. The levels of plasma 
GDF11 had a significantly positive correlation with the 
values of QMVC % predicted in the COPD patients (r = 0.37, 
p = 0.009, Figure 3A). Since exercise capacity is related to 
quadriceps strength in COPD,22,23 we further investigated 
correlations between the GDF11 levels and the 6MWD. 
The levels of plasma GDF11 had a significantly positive 
correlation with the 6MWD in the COPD patients (r = 0.43, 
p , 0.001, Figure 3B).
GDF11 and inflammatory markers
Since cellular senescence is reported to be associated with 
systemic inflammation in COPD,8–10 and GDF11, anti-aging 
Figure 1 Correlations between the levels of gDF11 and lung function data.
Notes: Correlations between the levels of plasma gDF11 and the values of FeV1 % predicted (A), FVC % predicted (B), IC (C), and Dlco’ % predicted (D) were investigated. 
Data were statistically analyzed by the spearman’s rank test. Closed circles (gray): gOlD stage I/II; closed circles (black): gOlD stage III/IV.
Abbreviations: Dlco’, diffusing capacity of the lung for carbon monoxide; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; gDF11, growth differentiation 
factor 11; gOlD, global Initiative for Chronic Obstructive lung Disease; IC, inspiratory capacity.
? ? ?? ??????? ??????????
???
????
???
?
???
???
???
??? ?????????????????
?
? ? ?? ?????? ??????????
???
????
???
?
??????
???
???
??? ?????????????????
?
? ? ?? ???????
???
????
???
?
?
???
???
??? ?????????????????
?
? ? ?? ????????? ??????????
???
????
???
?
???
???
???
??? ?????????????????
?
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
6.
77
.5
6.
92
 o
n 
21
-A
pr
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2018:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1337
gDF11 and physical activity in COPD
factor, reportedly possesses anti-inflammatory effects,15,24 we 
investigated the associations between the levels of plasma 
GDF11 and inflammatory markers, including IL-6, hs-CRP, 
fibrinogen, and MDA. We found that the levels of plasma 
GDF11 had negative correlations with the values of IL-6 
(r = −0.36, p = 0.002, Figure 4A) and hs-CRP (r = −0.31, 
p = 0.007, Figure 4B), but not with those of fibrinogen 
(r = −0.13, p = 0.368, Figure 4C) or MDA (r = −0.15, 
p = 0.263, Figure 4D).
Analysis of factors that influenced GDF11
We investigated the factors that influenced GDF11. We ana-
lyzed the factors related to the levels of plasma GDF11 by 
single linear regression analysis (Table 3). The data of lung 
function (FVC % predicted, β = 0.64, p , 0.001; FEV
1
 % 
predicted, β = 0.43, p , 0.001; IC, β = 0.66, p , 0.001; 
D
Lco
’ % predicted, β = 0.31, p = 0.001), 6MWD (β = 0.48, 
p , 0.001), the number of steps (β = 0.28, p , 0.001), the 
amounts of IL-6 (β = −0.21, p = 0.020), and QMVC % 
Table 2 Physical activity in the study subjects
Control COPD
GOLD I/II GOLD III/IV
subjects, n 18 37 33
number of steps per day 6,844 (4,935–7,832) 5,460 (2,527–7,840) 1,744 (716–4,543)**,‡
Duration of $2.0 MeTs, min/day 177 (143–254) 162 (92–225) 83 (58–157)*,‡
Duration of $2.5 MeTs, min/day 84 (63–143) 71 (35–95) 27 (11–62)**,‡
Duration of $3.0 MeTs, min/day 37 (25–51) 25 (12–43) 8 (3–19)**,‡
Notes: Data are presented as median (IQr). *p , 0.01, **p , 0.001 versus control, ‡p , 0.01 versus gOlD I/II.
Abbreviations: gOlD, global Initiative for Chronic Obstructive lung Disease; MeTs, metabolic equivalents; IQr, interquartile range.
Figure 2 Correlations between the levels of gDF11 and physical activity.
Notes: Correlations between the levels of plasma gDF11 and parameters of physical activity including the number of steps (A), duration of $2.0 MeTs (B), $2.5 MeTs (C), 
and $3.0 MeTs (D) were investigated. r is the correlation coefficient. Data were statistically analyzed by the Spearman’s rank test. Closed circles (gray): GOLD stage I/II; 
closed circles (black): gOlD stage III/IV.
Abbreviations: gDF11, growth differentiation factor 11; gOlD, global Initiative for Chronic Obstructive lung Disease; MeTs, metabolic equivalents.
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predicted (β = 0.64, p , 0.001) were significantly related 
to the levels of plasma GDF11 (Table 3). We further 
investigated the data by multiple regression analysis in the 
COPD group (Table 4). We found that the number of steps 
(β = 0.20, p = 0.045) was significantly related to the GDF11 
(Table 4) independent of the lung function, suggesting that 
the physical activity might be a predictor of the levels of 
plasma GDF11 in COPD.
Figure 4 Correlations between the levels of GDF11 and systemic inflammatory markers.
Notes: Correlations between the levels of plasma gDF11 and the amounts of Il-6 (A), hs-CrP (B), fibrinogen (C), and MDa (D) were investigated. r is the correlation 
coefficient. Data were analyzed by the Spearman’s rank test. Closed circles (gray): GOLD stage I/II; closed circles (black): GOLD stage III/IV.
Abbreviations: gDF11, growth differentiation factor 11; gOlD, global Initiative for Chronic Obstructive lung Disease; hs-CrP, high sensitivity C-reactive protein; Il-6, 
interleukin-6; MDa, malondialdehyde.
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Figure 3 Correlations between the levels of gDF11 and muscle strength and exercise capacity.
Notes: Correlations between the levels of plasma gDF11 and the QMVC % predicted (A) and the 6MWD (B) were investigated. r is the correlation coefficient. Data were 
statistically analyzed by the spearman’s rank test. Closed circles (gray): gOlD stage I/II; closed circles (black): gOlD stage III/IV.
Abbreviations: gDF11, growth differentiation factor 11; gOlD, global Initiative for Chronic Obstructive lung Disease; 6MWD, 6-minute walking distance; QMVC, 
quadriceps maximal voluntary contraction.
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Table 3 single regression analysis of plasma gDF11 in COPD 
patients
Variables GDF11
β* p-value
age (years) −0.33 0.611
smoking −0.06 0.576
FVC % predicted 0.64 ,0.001
FeV1 % predicted 0.43 ,0.001
IC 0.66 ,0.001
Dlco’ % predicted 0.31 0.001
6MWD 0.48 ,0.001
number of steps 0.28 ,0.001
Il-6 −0.21 0.020
QMVC % predicted 0.64 ,0.001
Notes: β* = regression coefficient. All data were log transformed. Data were 
analyzed by single linear regression analysis.
Abbreviations: Dlco’, diffusing capacity of the lung for carbon monoxide; FeV1, 
forced expiratory volume in 1 second; FVC, forced vital capacity; gDF11, growth 
differentiation factor 11; IC, inspiratory capacity; Il-6, interleukin-6; 6MWD, 
6-minute walking distance; QMVC, quadriceps maximal voluntary contraction.
Table 4 Multiple regression analysis of plasma gDF11 in the 
COPD patients
Variables GDF11
β* p-value
smoking 0.23 0.078
FeV1 % predicted 0.05 0.735
6MWD 0.02 0.908
number of steps 0.20 0.045
Il-6 −0.01 0.909
QMVC % predicted 0.31 0.093
Notes: β* = regression coefficient. All data were log transformed. Data were 
analyzed by multivariate linear regression. R2 =0.50 (adjusted R2 =0.42).
Abbreviations: FeV1, forced expiratory volume in 1 second; gDF11, growth 
differentiation factor 11; Il-6, interleukin-6; 6MWD, 6-minute walking distance; 
QMVC, quadriceps maximal voluntary contraction.
Discussion
The present study demonstrated that the levels of plasma 
GDF11, an anti-aging and rejuvenating factor, were signifi-
cantly correlated with the lung function, levels of physical 
activity, quadriceps strength, exercise capacity, and systemic 
inflammatory markers. In addition, the multiple regres-
sion analysis showed that the number of steps was related 
to GDF11 in COPD. These results suggest that physical 
activity might be associated with the decreased plasma 
GDF11 in COPD.
In this study, we demonstrated that the levels of plasma 
GDF11 had significant correlations with the values of FEV
1
 
% predicted and D
Lco
’ % predicted, and were compatible with 
those of a previous study.15 In addition, we showed correla-
tions between the levels of plasma GDF11 and the values of 
FVC % predicted and IC. These findings support that GDF11 
may be related to the pathogenesis of COPD. In our previ-
ous study, we demonstrated that the production of GDF11 
in the lungs of the COPD patients was decreased compared 
with the control subjects.15 Moreover, treatment with GDF11 
inhibited the CSE-induced cellular senescence in vitro.15 
These findings suggested that GDF11 in lungs could possess 
an anti-senescent effect. However, the causes of the decrease 
in circulating GDF11 remain unclear, although the levels of 
plasma GDF11 in COPD patients were decreased compared 
with those in control subjects.15 One possible explanation is 
that the plasma GDF11 might spill over from the lungs into 
the blood stream because the expression of GDF11 in the 
lungs was decreased in COPD. Another possible explana-
tion is that GDF11 is highly expressed in skeletal muscle,12 
less so in lungs, suggesting that circulating GDF11 could be 
derived from skeletal muscles. In fact, many studies reported 
that limb muscle atrophy and weakness were observed in 
COPD patients.25,26 These findings prompted us to investi-
gate the relationships between plasma GDF11 and clinical 
parameters, including physical activity. Actually, we found 
that the levels of plasma GDF11 had positive correlations 
with the quadriceps strength and physical activity in the 
present study. Furthermore, we demonstrated an associa-
tion between the levels of plasma GDF11 and the exercise 
capacity. Exercise capacity was reported to be related to 
physical activity19,27 and quadriceps strength22,23 in COPD. 
Therefore, the levels of plasma GDF11 could be correlated 
with the 6MWD in the current study. In a previous study, 
the administration of GDF11 regenerated the injured muscle 
and restored the satellite cell function, resulting in increased 
muscle strength and exercise endurance in aged mice.14 
Taken together, GDF11 might be a possible therapeutic 
approach for the muscle weakness of COPD. Further study 
is needed to reveal the effects of GDF11 on the muscle 
dysfunction in COPD.
Conversely, some myokines, including IL-6 and irisin 
were reportedly produced and released from contracting 
skeletal muscle into the circulation during exercise in healthy 
subjects.28–30 In addition, irisin was also upregulated after 
exercise in patients with COPD.31 However, it has not been 
elucidated whether the circulating GDF11 was increased by 
muscle contraction. Because GDF11 could increase muscle 
strength and endurance, it would be of interest to explore 
whether improvement of the physical activity could increase 
the production of circulating GDF11. To clarify this issue, 
we should investigate whether pulmonary rehabilitation or 
exercise training can improve the levels of circulating GDF11 
in patients with COPD.
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In the current study, we demonstrated that the levels of 
plasma GDF11 had negative correlations with the amounts 
of IL-6 and hs-CRP. Previous reports showed that physical 
inactivity in patients with COPD could cause systemic 
inflammation.32,33 Therefore, the levels of plasma GDF11 might 
be correlated with the levels of inflammatory markers. Alter-
natively, GDF11 was reported to possess anti-inflammatory 
effects in vitro and in vivo studies.15,24 Thus, the decrease 
in GDF11 might be the cause of the systemic inflammation 
observed in COPD. No correlations were found between the 
levels of plasma GDF11 and the levels of MDA. MDA might 
be an insensitive marker of lipid peroxidation in the whole 
body, so the levels of MDA were not correlated with those 
of GDF11 in this study.
There are some limitations in this study. First, we could not 
measure the actual amounts of plasma GDF11 because they 
were semi-quantified by immunoblotting. We should establish 
a new quantitative method, such as the liquid chromatography 
with tandem mass spectrometry method to measure the actual 
amounts of GDF11. Second, the sample size of this study was 
relatively small. Our results should be verified in another study 
with larger cohorts to confirm our findings.
Conclusion
Our findings suggest that physical inactivity was associated 
with the decreased circulating GDF11, which might be useful 
for understanding the pathogenesis of COPD. Clarifying the 
relationships between the physical inactivity and GDF11 
may provide a potentially attractive therapeutic approach in 
COPD via increasing the circulating GDF11.
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Supplementary material
Figure S1 levels of gDF11 in plasma.
Notes: Plasma was obtained from the control subjects, gOlD stage I/II and gOlD stage III/IV COPD patients. The levels of plasma gDF11 were investigated by 
immunoblotting (A). Ponceau s staining was used to evaluate the amounts of protein. The gDF11 levels were calculated by measuring the intensity of the bands (B). Open 
circles: control; closed circles (gray): gOlD stage I/II; closed circles (black): gOlD stage III/IV. results are expressed mean ± sD. Data were analyzed with one-way anOVa 
followed by Tukey’s test. ***p , 0.001 compared with control; +++p , 0.001 compared with gOlD stage I/II.
Abbreviations: anOVa, analysis of variance; gDF11, growth differentiation factor 11; gOlD, global Initiative for Chronic Obstructive lung Disease; M, molecular 
weight marker.
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